|
1
|
Chang SJ, Bristow RE, Chi DS and Cliby WA:
Role of aggressive surgical cytoreduction in advanced ovarian
cancer. J Gynecol Oncol. 26:336–342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kujawa KA and Lisowska KM: Ovarian
cancer-from biology to clinic. Postepy Hig Med Dosw (Online).
69:1275–1290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dinkelspiel HE, Champer M, Hou J, Tergas
A, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL and Wright
JD: Long-term mortality among women with epithelial ovarian cancer.
Gynecol Oncol. 138:421–428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Devi Uma K, Purushotham N and Jayashree N:
Management of ovarian cancer in younger women. Rev Recent Clin
Trials. 10:263–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gasparri ML, Attar R, Palaia I, Perniola
G, Marchetti C, Di Donato V, Farooqi AA, Papadia A and Panici PB:
Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J
Cancer Prev. 16:3635–3638. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grisham RN, Hyman DM and Iyer G: Targeted
therapies for treatment of recurrent ovarian cancer. Clin Adv
Hematol Oncol. 12:158–162. 2014.PubMed/NCBI
|
|
7
|
Au KK, Josahkian JA, Francis JA, Squire JA
and Koti M: Current state of biomarkers in ovarian cancer
prognosis. Future Oncol. 11:3187–3195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong X, Men X, Zhang W and Lei P: Advances
in tumor markers of ovarian cancer for early diagnosis. Indian J
Cancer. 51 Suppl 3:e72–e76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Slezak-Prochazka I, Durmus S, Kroesen BJ
and van den Berg A: MicroRNAs, macrocontrol: Regulation of miRNA
processing. RNA. 16:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu J, Wang S, Zhang W, Qiu J, Shan Y,
Yang D and Shen B: Screening key microRNAs for castration-resistant
prostate cancer based on miRNA/mRNA functional synergistic network.
Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun X and Zhang J: Dysfunctional
miRNA-mediated regulation in chromophobe renal cell carcinoma. PLoS
One. 11:e01563242016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sathyapalan T, David R, Gooderham NJ and
Atkin SL: Increased expression of circulating miRNA-93 in women
with polycystic ovary syndrome may represent a novel, non-invasive
biomarker for diagnosis. Sci Rep. 5:168902015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Min L, Ren C, Xu X, Yang J, Sun X,
Wang T, Wang F, Sun C and Zhang X: miRNA-148a serves as a
prognostic factor and suppresses migration and invasion through
Wnt1 in non-small cell lung cancer. PLoS One. 12:e01717512017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zedan AH: Heterogeneity of miRNA
expression in localized prostate cancer with clinicopathological
correlations. PLoS One. 12:e01791132017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gautam A, Kumar R, Dimitrov G, Hoke A,
Hammamieh R and Jett M: Identification of extracellular miRNA in
archived serum samples by next-generation sequencing from RNA
extracted using multiple methods. Mol Biol Rep. 43:1165–1178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura K, Sawada K, Yoshimura A, Kinose
Y, Nakatsuka E and Kimura T: Clinical relevance of circulating
cell-free microRNAs in ovarian cancer. Mol cancer. 15:482016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li SP, Su HX, Zhao D and Guan QL: Plasma
miRNA-506 as a prognostic biomarker for esophageal squamous cell
carcinoma. Med Sci Monitor. 22:2195–2201. 2016. View Article : Google Scholar
|
|
18
|
Tijsen AJ, Creemers EE, Moerland PD, de
Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a
circulating biomarker for heart failure. Circ Res. 106:1035–1039.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo P, He T, Jiang R and Li G:
MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in
cardiomyocytes. Mol Med Rep. 12:1163–1168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Zeng A, Hu Q, Yan W, Liu Y and You
Y: miR-423-5p contributes to a malignant phenotype and temozolomide
chemoresistance in glioblastomas. Neuro Oncol. 19:55–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stiuso P, Potenza N, Lombardi A,
Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N,
Castiello F, Porto S, et al: MicroRNA-423-5p promotes autophagy in
cancer cells and is increased in serum from hepatocarcinoma
patients treated with sorafenib. Mol Ther Nucleic Acids.
4:e2332015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang Z, Tang J, Bai Y, Lin H, You H, Jin
H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24,
microRNA-320a and microRNA-423-5p are potential biomarkers for
colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai L, Cui X, Zhang X, Cheng L, Liu Y,
Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits
angiogenesis and tumour growth of human colon cancer through
directly targeting ceruloplasmin. Nat Commun. 7:119962016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Falcetta FS, Lawrie TA, Medeiros LR, da
Rosa MI, Edelweiss MI, Stein AT, Zelmanowicz A, Moraes AB, Zanini
RR and Rosa DD: Laparoscopy vs. laparotomy for FIGO stage I ovarian
cancer. Cochrane Database Syst Rev. 10:CD0053442016.PubMed/NCBI
|
|
26
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang H, Jiang Z, Xie G and Lu Y: Serum
microRNA-145 as a novel biomarker in human ovarian cancer. Tumour
Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ali S, Saleh H, Sethi S, Sarkar FH and
Philip PA: MicroRNA profiling of diagnostic needle aspirates from
patients with pancreatic cancer. Br J Cancer. 107:1354–1360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wan Y, Fei X, Wang Z, Jiang D, Chen H,
Wang M and Zhou S: miR-423-5p knockdown enhances the sensitivity of
glioma stem cells to apigenin through the mitochondrial pathway.
Tumour Biol. 39:10104283176955262017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Wang X, Yang X, Liu Y, Shi Y, Ren J
and Guleng B: miRNA423-5p regulates cell proliferation and invasion
by targeting trefoil factor 1 in gastric cancer cells. Cancer Lett.
347:98–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Zeng A, Hu Q, Yan W, Liu Y and You
Y: miR-423-5p contributes to a malignant phenotype and temozolomide
chemoresistance in glioblastomas. Neuro Oncol. 19:55–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
